Aktivolabs Co-Founders Gourab Mukherjee, Dr Meng-Han Kuok, and Professor David Lai
Singapore-based digital health-science company Aktivolabs has secured US$10 million in a Series A round of investment led by Mitsui & Co, Adaptive Capital Partners, and SEEDS Capital.
HH Investments and Govin Capital also participated.
The funds will be utilised to grow Aktivolabs’s data science capability, strengthen the team and portfolio of products, and broaden its footprint in Southeast Asia, Europe, and the US.
The company will develop the existing algorithm and data-analytics programme to enhance the efficiency and accuracy of predicting, preventing and self-managing chronic disease using digital biomarkers.
“This investment will enable us to deliver an integrated platform to exacting standards, strengthen our customer-servicing capability, and help populations better understand and manage their risk of chronic diseases through individualising digital health journeys,” said Gourab Mukherjee, Co-Founder and CEO of Aktivolabs.
Also Read: How Malaysia is championing regenerative medicine technology
Aktivolabs was co-founded in 2017 by the late Professor David Lai Gourab Mukherjee and Dr Meng-Han Kuok. It provides accessible, affordable, evidence-based, and individualised digital health solutions that help populations understand and manage their risk of chronic diseases.
The platform harnesses real-time digital health data elements in a low-touch, cost-effective manner with measurable actuarial and actionable value to life and health insurers.
It functions as a real-time action decision engine to drive hyper-personalised financial and insurance product development, generates pay-as-you-live insurance products and provides deeper customer experience tailored to client engagement through its proprietary experiential technology.
The current product portfolio includes the Aktivo Score, Aktivo Mind, Glucolife and Goodbiome.
Aktivolabs currently operates in Singapore, Hong Kong, India, Japan, Australia, Philippines, Taiwan, Malaysia, Indonesia, Vietnam, Thailand, Macau and the UAE and is growing worldwide.
“It’s commonly known that the early onset of chronic diseases compromises our financial and mental well-being, and the fast-rising cost of healthcare poses major challenges for populations, governments, insurers and employers worldwide. At the intersection of healthcare, science and data, Aktivolabs’s evidence-based solution deploys its full suite of accessible, affordable, scalable data-scientific solutions through digital biomarkers and individualised health journeys,” says Takeshi Akutsu, CTO (Wellness Business Unit) at Mitsui.
—
Fundraising or preparing your startup for fundraising? Build your investor network, search from 400+ SEA investors on e27, and get connected or get insights regarding fundraising. Try e27 Pro for free today.
The post Aktivolabs scores US$10M Series A to help populations manage risk of chronic diseases appeared first on e27.